{"content":"<li class=\"n-box-item date-title\" data-end=\"1508385599\" data-start=\"1508299200\" data-txt=\"Monday, December 23, 2019\">Wednesday, October 18, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3302038\" data-ts=\"1508369837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMI\" target=\"_blank\">KMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302038-kinder-morgan-moves-higher-dividend-hike-planned-for-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kinder Morgan moves higher as dividend hike planned for 2018</a></h4><ul>     <li>Kinder Morgan (NYSE:<a href='https://seekingalpha.com/symbol/KMI' title='Kinder Morgan, Inc.'>KMI</a>) <font color='green'>+1.8%</font>&nbsp;after-hours as a mixed <a href=\"https://seekingalpha.com/news/3301931-kinder-morgan-eps-line-beats-revenue\" target=\"_blank\">Q3 earnings</a> result is outweighed by news that it will increase the annual dividend to $0.80/share for 2018, starting with $0.20 for Q1.</li>     <li>\"Our goal of maintaining robust dividend coverage while delivering a substantial dividend increase to stockholders out of operating cash flows in excess of growth  capital remains clearly in sight,\" says Executive Chairman Richard Kinder.</li>     <li>KMI says it expects to end the year with a net debt-to-adjusted EBITDA ratio of ~5.2x, as proceeds from the Kinder Morgan Canada IPO were used to pay down debt; growth capital investment of $3.1B; and distributable cash flow less than 1% below budget.</li>     <li>KMI's Q3 earnings finished in-line with estimates while <a href=\"http://www.reuters.com/article/us-kinder-morgan-de-results/kinder-morgans-revenue-beats-as-natgas-volumes-rise-idUSKBN1CN2XP\" target=\"_blank\">revenues slipped 1.5%</a>, partly due to the Canada IPO and the impact of Hurricane Harvey as KMI shut down some of its pipelines and gas storage facilities.</li>     <li>Q3 natural gas gathering volumes fell 14% Y/Y and crude and condensate pipeline volumes slid 8% due mostly to Harvey, but natural gas transport volumes rose 3%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3302038\" data-linked=\"Kinder Morgan moves higher as dividend hike planned for 2018\" data-tweet=\"$KMI - Kinder Morgan moves higher as dividend hike planned for 2018 https://seekingalpha.com/news/3302038-kinder-morgan-moves-higher-dividend-hike-planned-for-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3302038-kinder-morgan-moves-higher-dividend-hike-planned-for-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302036\" data-ts=\"1508368384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRCO\" target=\"_blank\">TRCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302036-fcc-pauses-review-of-3_9b-sinclair-tribune-deal-for-comment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FCC pauses review of $3.9B Sinclair-Tribune deal for more comment</a></h4><ul>   <li>The FCC is <a href=\"https://www.reuters.com/article/us-tribune-media-m-a-sinclair-ma/u-s-fcc-extends-comment-period-for-sinclair-tribune-deal-idUSKBN1CN37B\" target=\"_blank\">pausing its review</a> of Sinclair Broadcast Group's (<a href=\"http://seekingalpha.com/symbol/SBGI\" target=\"_blank\">SBGI</a> <font color='green'>+1%</font>) $3.9B bid for Tribune Media (NYSE:<a href='https://seekingalpha.com/symbol/TRCO' title='Tribune Media Company'>TRCO</a>) to extend the public comment period.</li>    <li>The agency usually runs a self-imposed 180-day \"shot clock\" to complete reviews; it's moving that by 15 days, until Nov. 2.</li>    <li>The deal -- from the nation's biggest local broadcaster, a conservative media organization -- has come under fire from a number of sources, including conservative media and liberal advocacy groups, as well as industry participants like Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color='green'>+1.8%</font>).</li>    <li>A combination with Tribune would extend Sinclair's reach to 72% of American households, which opponents argue is too much influence over local news content.</li>    <li>FCC Chairman Ajit Pai said in April he'd start a \"comprehensive review\" of media regulations regarding consolidation, but hasn't launched a formal proceeding yet.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3302036\" data-linked=\"FCC pauses review of $3.9B Sinclair-Tribune deal for more comment\" data-tweet=\"$TRCO $TRCO $SBGI - FCC pauses review of $3.9B Sinclair-Tribune deal for more comment https://seekingalpha.com/news/3302036-fcc-pauses-review-of-3_9b-sinclair-tribune-deal-for-comment?source=tweet\" data-url=\"https://seekingalpha.com/news/3302036-fcc-pauses-review-of-3_9b-sinclair-tribune-deal-for-comment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302030\" data-ts=\"1508365652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302030-gilead-cancer-therapy-drug-acquired-via-kite-pharma-wins-fda-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead cancer therapy drug acquired via Kite Pharma wins FDA approval</a></h4><ul>     <li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>)&nbsp;<font color='green'>+3.7%</font> after-hours as the <a href=\"https://seekingalpha.com/pr/16973002-kite-s-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-fda-treatment\" target=\"_blank\">FDA approves</a> a new cancer therapy for a type of lymphoma developed by Kite Pharma, which GILD <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11_9b-cash-kite-16-percent-premarket\" target=\"_blank\">acquired in August </a>for $11.9B.</li>     <li>The drug, Yescarta, has been among the <a href=\"https://www.wsj.com/articles/gilead-cell-therapy-drug-yescarta-gets-fda-approval-1508364454\" target=\"_blank\">most highly anticipated new drugs on Wall Street</a>, as the therapy is projected to total $1.7B in worldwide sales in five years.</li>     <li>Yescarta is the second in a new class of cancer treatments called chimeric antigen receptor T-cell therapy, or CAR-T, which reprograms the body's own immune cells to recognize and attack malignant cells; the first drug in the class, Novartis's Kymriah, was approved in August.</li></ul><div class=\"tiny-share-widget\" data-id=\"3302030\" data-linked=\"Gilead cancer therapy drug acquired via Kite Pharma wins FDA approval\" data-tweet=\"$GILD - Gilead cancer therapy drug acquired via Kite Pharma wins FDA approval https://seekingalpha.com/news/3302030-gilead-cancer-therapy-drug-acquired-via-kite-pharma-wins-fda-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3302030-gilead-cancer-therapy-drug-acquired-via-kite-pharma-wins-fda-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302024\" data-ts=\"1508363930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESTE\" target=\"_blank\">ESTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302024-earthstone-energy-to-launch-4_5m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Earthstone Energy to launch 4.5M-share offering</a></h4><ul>     <li>Earthstone Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/ESTE' title='Earthstone Energy, Inc.'>ESTE</a>) <font color='red'>-6.5%</font> after-hours as it commences a <a href=\"https://seekingalpha.com/filing/3731436#ESTE-EX992_16_HTM\" target=\"_blank\">public offering</a> of 4.5M common shares, with an underwriters option to purchase up to an additional 675K shares.</li>     <li>ESTE says it plans to use the proceeds to repay outstanding debt under its revolving credit facility.</li>     <li>ESTE also estimates Q3 production of 9,671 boe/day and lowers its estimated FY 2017 capex to $85M from $115M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3302024\" data-linked=\"Earthstone Energy to launch 4.5M-share offering\" data-tweet=\"$ESTE - Earthstone Energy to launch 4.5M-share offering https://seekingalpha.com/news/3302024-earthstone-energy-to-launch-4_5m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3302024-earthstone-energy-to-launch-4_5m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302020\" data-ts=\"1508363055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302020-nielsen-launches-new-measurement-for-subscription-streaming-video\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nielsen launches new measurement for subscription streaming video</a></h4><ul>   <li>Nielsen (<a href=\"http://seekingalpha.com/symbol/NLSN\" target=\"_blank\">NLSN</a> <font color='green'>+4.2%</font>) launched its Subscription Video On Demand Content Ratings, a syndicated move to <a href=\"https://seekingalpha.com/pr/16972363-new-nielsen-service-shines-light-subscription-based-streaming-content-consumption\" target=\"_blank\">tap into viewing of streaming media</a>.</li>    <li>Eight networks and studios have signed on, it says, including A&amp;E, Disney-ABC (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>), Lionsgate (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a>), NBCUniversal (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>), and Warner Bros. (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>).</li>    <li>While Nielsen began measuring streaming content through an opt-in service three years ago, new enhancements use demographic and household characteristic data to offer a more comprehensive view.</li>    <li>The company is promising measurement \"at the season and episode level in a manner comparable to linear television data -- including ratings, reach, frequency and segmentation reporting.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3302020\" data-linked=\"Nielsen launches new measurement for subscription streaming video\" data-tweet=\"$DIS $DIS $LGF.A - Nielsen launches new measurement for subscription streaming video https://seekingalpha.com/news/3302020-nielsen-launches-new-measurement-for-subscription-streaming-video?source=tweet\" data-url=\"https://seekingalpha.com/news/3302020-nielsen-launches-new-measurement-for-subscription-streaming-video\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302018\" data-ts=\"1508362777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302018-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> <font color='green'>+10.9%</font>. <a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a> <font color='green'>+6.9%</font>. <a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='green'>+5.8%</font>. <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+1.6%</font>. <a href='https://seekingalpha.com/symbol/BDN' title='Brandywine Realty Trust'>BDN</a> <font color='green'>+1.5%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a> <font color='red'>-5.4%</font>. <a href='https://seekingalpha.com/symbol/PEGI' title='Pattern Energy Group Inc.'>PEGI</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/YRCW' title='YRC Worldwide, Inc.'>YRCW</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='red'>-2.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3302018\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$LLNW $ADBE $CNAT - After Hours Gainers / Losers https://seekingalpha.com/news/3302018-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3302018-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302014\" data-ts=\"1508362017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302014-blue-apron-lowers-headcount-6-in-realignment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron lowers headcount by 6% in realignment</a></h4><ul>     <li>Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) is cutting about 6% of its workforce as part of a company-wide realignment.</li>     <li>The company expects to see ~$3.5M in employee-related expenses during Q4 as a result of the action.</li><li><a href=\"https://seekingalpha.com/filing/3731400\" target=\"_blank\">SEC Form 8-K</a></li><li>Shares of Blue Apron are&nbsp;<font color='red'>down 1%</font>&nbsp;in AH trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3302014\" data-linked=\"Blue Apron lowers headcount by 6% in realignment\" data-tweet=\"$APRN - Blue Apron lowers headcount by 6% in realignment https://seekingalpha.com/news/3302014-blue-apron-lowers-headcount-6-in-realignment?source=tweet\" data-url=\"https://seekingalpha.com/news/3302014-blue-apron-lowers-headcount-6-in-realignment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302012\" data-ts=\"1508361702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEGI\" target=\"_blank\">PEGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302012-pattern-energy-to-launch-8m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pattern Energy to launch 8M-share offering</a></h4><ul>     <li>Pattern Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/PEGI' title='Pattern Energy Group Inc.'>PEGI</a>) <font color='red'>-4.4%</font> after-hours as it commences a <a href=\"https://seekingalpha.com/pr/16972889-pattern-energy-announces-commencement-public-offering-class-common-stock\" target=\"_blank\">public offering</a> of 8M common shares, with an underwriters option to purchase up to an additional 1.2M shares.</li>     <li>PEGI says it plans to use the proceeds for general corporate purposes, which may include funding acquisitions, dropdowns or investments, or to pay down debt.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3302012\" data-linked=\"Pattern Energy to launch 8M-share offering\" data-tweet=\"$PEGI - Pattern Energy to launch 8M-share offering https://seekingalpha.com/news/3302012-pattern-energy-to-launch-8m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3302012-pattern-energy-to-launch-8m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3302001\" data-ts=\"1508360245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3302001-native-american-tribe-suing-microsoft-amazon-over-patents-holds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Native American tribe suing Microsoft, Amazon over patents it holds</a></h4><ul><li>        The Saint Regis Mohawk Tribe <a href=\"http://www.reuters.com/article/us-usa-patents-nativeamerican/native-american-tribe-holding-patents-sues-amazon-and-microsoft-idUSKBN1CN2G1\" target=\"_blank\">is suing</a> Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) and Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) in federal court for violating patents the tribe holds for SRC Labs.</li><li>               Companies sued for patent infringement often ask the patent board to invalidate the patents in question. Turning the patents over to a Native American tribe uses its sovereign status to block the patents from administrative review.&nbsp;</li><li>               Allergan recently gave the same tribe its patents for dry eye treatment Restasis.&nbsp;</li><li>                  SRC is also a plaintiff and the tribe would share in any potential reward.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3294452-allergan-uses-legal-maneuver-sovereign-tribal-government-protect-restasis-patents\" target=\"_blank\">Allergan uses legal maneuver with sovereign tribal government to protect Restasis patents</a> (Sept. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3302001\" data-linked=\"Native American tribe suing Microsoft, Amazon over patents it holds\" data-tweet=\"$MSFT $MSFT $AMZN - Native American tribe suing Microsoft, Amazon over patents it holds https://seekingalpha.com/news/3302001-native-american-tribe-suing-microsoft-amazon-over-patents-holds?source=tweet\" data-url=\"https://seekingalpha.com/news/3302001-native-american-tribe-suing-microsoft-amazon-over-patents-holds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301996\" data-ts=\"1508359775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCA\" target=\"_blank\">HCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301996-hca-sees-4-increase-in-q3-revenues-9-drop-in-non-gaap-ebitda-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HCA sees ~4% increase in Q3 revenues, but 9% drop in non-GAAP EBITDA; shares down 4% after hours</a></h4><ul><li>On a preliminary basis, HCA Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a>) <a href=\"https://seekingalpha.com/pr/16972899-hca-previews-2017-third-quarter-results\" target=\"_blank\">expects </a>Q3's top line to be ~$10.696B (+4.1%) and ~$1.776B (-9.2%) in non-GAAP EBITDA.</li><li>EPS should be $1.15 (-27.7%) but includes losses on the retirement of debt ($0.07 per share).</li><li>Another $0.24 per share was lost due to expenses associated with recent hurricanes in addition to an $0.08/share hit related to the Texas Medicaid Waiver program.</li><li><strong>Updated guidance</strong>: Revenues: $43B - 44B; non-GAAP EBITDA: $8.00B - 8.15B; EPS: $6.45 - 6.70.</li><li>Consensus view is EPS of $1.57 on revenues of $10.67B.</li><li>Complete results will be released on or about October 31.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301996\" data-linked=\"HCA sees ~4% increase in Q3 revenues, but 9% drop in non-GAAP EBITDA; shares down 4% after hours\" data-tweet=\"$HCA - HCA sees ~4% increase in Q3 revenues, but 9% drop in non-GAAP EBITDA; shares down 4% after hours https://seekingalpha.com/news/3301996-hca-sees-4-increase-in-q3-revenues-9-drop-in-non-gaap-ebitda-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3301996-hca-sees-4-increase-in-q3-revenues-9-drop-in-non-gaap-ebitda-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301977\" data-ts=\"1508358896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301977-fda-ad-com-backs-novos-semaglutide-for-t2d-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com backs Novo&#39;s semaglutide for T2D; shares up 2% after hours</a></h4><ul><li>The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval for Novo Nordisk's (NYSE:<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a>) once-weekly semaglutide as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours on robust volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301213-ad-com-review-wednesday-novo-nordisks-semaglutide-t2d\" target=\"_blank\">Ad Com review Wednesday for Novo Nordisk's semaglutide for T2D</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301977\" data-linked=\"FDA Ad Com backs Novo&#39;s semaglutide for T2D; shares up 2% after hours\" data-tweet=\"$NVO - FDA Ad Com backs Novo&#39;s semaglutide for T2D; shares up 2% after hours https://seekingalpha.com/news/3301977-fda-ad-com-backs-novos-semaglutide-for-t2d-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3301977-fda-ad-com-backs-novos-semaglutide-for-t2d-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301958\" data-ts=\"1508358150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301958-light-profit-guidance-sends-ebay-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Light profit guidance sends eBay lower</a></h4><ul>     <li>EBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>) reports that <a href=\"https://seekingalpha.com/pr/16972863-ebay-inc-reports-third-quarter-2017-results\" target=\"_blank\">Q3</a> gross merchandising volume rose 8% Y/Y to $21.7B. GMV was up 7% on a currency neutral basis.&nbsp;Marketplace GMV increased 9% on an as-reported basis and 7% on a currency neutral basis.</li>     <li>The company says it added just short of 2M&nbsp;active buyers across its platforms and now has a total of 168M global active buyers.</li>     <li>Non-GAAP operating margin fell 30 bps to 29.6% during the quarter.</li>     <li>Looking ahead, eBay sees Q4 revenue of $2.58-2.62B vs. $2.58B consensus and FY17 revenue of $9.53-9.57B vs. $9.49B consensus. Guidance for FY17 EPS came in at $1.99 to $2.01 vs. $2.02 consensus.</li>     <li>EBAY&nbsp;<font color='red'>-4.13%</font>&nbsp;AH to $36.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301958\" data-linked=\"Light profit guidance sends eBay lower\" data-tweet=\"$EBAY - Light profit guidance sends eBay lower https://seekingalpha.com/news/3301958-light-profit-guidance-sends-ebay-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3301958-light-profit-guidance-sends-ebay-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301946\" data-ts=\"1508357769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301946-ebay-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">eBay EPS in-line, beats on revenue</a></h4><ul><li>eBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>): Q3 EPS of $0.48 in-line.</li><li>Revenue of $2.41B (+8.6% Y/Y) <font color='green'>beats by $40M</font>.</li><li>Shares <font color='green'>+3.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16972863-ebay-inc-reports-third-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301946\" data-linked=\"eBay EPS in-line, beats on revenue\" data-tweet=\"$EBAY - eBay EPS in-line, beats on revenue https://seekingalpha.com/news/3301946-ebay-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301946-ebay-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301945\" data-ts=\"1508357755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URI\" target=\"_blank\">URI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301945-united-rentals-beats-0_27-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Rentals beats by $0.27, beats on revenue</a></h4><ul><li>United Rentals (NYSE:<a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a>): Q3 EPS of $3.25 <font color='green'>beats by $0.27</font>.</li><li>Revenue of $1.77B (+17.2% Y/Y) <font color='green'>beats by $60M</font>.</li><li>Shares <font color='green'>+3.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16972855-united-rentals-announces-third-quarter-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301945\" data-linked=\"United Rentals beats by $0.27, beats on revenue\" data-tweet=\"$URI - United Rentals beats by $0.27, beats on revenue https://seekingalpha.com/news/3301945-united-rentals-beats-0_27-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301945-united-rentals-beats-0_27-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301930\" data-ts=\"1508357203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXP\" target=\"_blank\">AXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301930-american-express-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Express beats by $0.02, beats on revenue</a></h4><ul><li>American Express (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>): Q3 EPS of $1.50 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $8.44B (+8.6% Y/Y) <font color='green'>beats by $150M</font>.</li><li>Shares <font color='green'>+1.65%</font>.</li><li><a href='https://seekingalpha.com/pr/16972804-american-express-reports-third-quarter-eps-1_50-25-percent'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301930\" data-linked=\"American Express beats by $0.02, beats on revenue\" data-tweet=\"$AXP - American Express beats by $0.02, beats on revenue https://seekingalpha.com/news/3301930-american-express-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301930-american-express-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301922\" data-ts=\"1508356946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLNW\" target=\"_blank\">LLNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301922-limelight-networks-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Limelight Networks beats by $0.02, beats on revenue</a></h4><ul><li>Limelight Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a>): Q3 EPS of $0.02 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $46.07M (+16.7% Y/Y) <font color='green'>beats by $2.98M</font>.</li><li>Shares <font color='green'>+4.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16972787-limelight-networks-r-reports-record-financial-results-third-quarter-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301922\" data-linked=\"Limelight Networks beats by $0.02, beats on revenue\" data-tweet=\"$LLNW - Limelight Networks beats by $0.02, beats on revenue https://seekingalpha.com/news/3301922-limelight-networks-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301922-limelight-networks-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301919\" data-ts=\"1508356303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTNT\" target=\"_blank\">FTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301919-fortinet-upped-to-buy-deutsche-bank-growth-story-underappreciated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortinet upped to Buy at Deutsche Bank as growth story underappreciated</a></h4><ul>     <li>Fortinet (<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a> <font color='green'>+2.6%</font>)&nbsp;is <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10193330/fortinets-underappreciated-growth-story\" target=\"_blank\">upgraded to Buy</a> from Hold with a $48 price target, raised from $36, at Deutsche Bank, which believes FTNT will continue to gain market share in the network security space and that the company exhibits an attractive revenue and free cash flow growth profile relative to its valuation.</li>     <li>Deutsche Bank notes FTNT holds slightly more than 10% share in network security today and is expected to gain nearly 20% share of the market's absolute dollar growth in 2017.</li>     <li>The firm also thinks Wall Street underestimates the benefits of FTNT's mix to subscription and that the company can meet or exceed revenue estimates during the next three years, even with conservative product growth assumptions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301919\" data-linked=\"Fortinet upped to Buy at Deutsche Bank as growth story underappreciated\" data-tweet=\"$FTNT - Fortinet upped to Buy at Deutsche Bank as growth story underappreciated https://seekingalpha.com/news/3301919-fortinet-upped-to-buy-deutsche-bank-growth-story-underappreciated?source=tweet\" data-url=\"https://seekingalpha.com/news/3301919-fortinet-upped-to-buy-deutsche-bank-growth-story-underappreciated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301915\" data-ts=\"1508355207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVX\" target=\"_blank\">CVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301915-chevron-slides-amid-two-downgrades-california-refinery-fire\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chevron slides amid two downgrades, California refinery fire</a></h4><ul>     <li>Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='red'>-1.7%</font>) is sharply lower after getting smacked by two analyst downgrades, as well as news of a <a href=\"https://seekingalpha.com/news/3301735-fire-extinguished-chevrons-el-segundo-refinery-california\" target=\"_blank\">large fire overnight</a> at its El Segundo refinery.</li>     <li>CVX was <a href=\"http://www.barrons.com/articles/petrobras-chevron-is-big-oil-still-a-big-deal-1508337122\" target=\"_blank\">downgraded</a> to Market Perform from Outperform by BMO analysts after the stock reached the firm's $120 price target, acknowledging the company's promising growth prospects but not enough to justify a widening valuation premium.</li>     <li>\"Taking consensus PE and EV/EBITDA multiples, CVX trades at 29% and 26% premiums to the sector averages,\"&nbsp;BMO writes. \"Given our flat price forecast, $55/bbl Brent until 2020, we do not anticipate any material upside for the shares, which already trade at a premium to their peers.\"</li>     <li>Societe Generale also cut CVX to Hold from Buy with a $130 price target, also citing valuation.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301915\" data-linked=\"Chevron slides amid two downgrades, California refinery fire\" data-tweet=\"$CVX - Chevron slides amid two downgrades, California refinery fire https://seekingalpha.com/news/3301915-chevron-slides-amid-two-downgrades-california-refinery-fire?source=tweet\" data-url=\"https://seekingalpha.com/news/3301915-chevron-slides-amid-two-downgrades-california-refinery-fire\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301912\" data-ts=\"1508354969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMDZ\" target=\"_blank\">IMDZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301912-immune-design-continues-freefall-down-20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immune Design continues freefall, down 20%</a></h4><ul><li>Thinly traded micro cap Immune Design (<a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-20.1%</font>) is getting roughed again, this time on more than a 9x surge in volume. Shares have cratered&nbsp;<font color='red'>40%</font>&nbsp;in three days following its <a href=\"https://seekingalpha.com/pr/16969704-immune-design-announces-positive-fda-feedback-phase-3-clinical-trial-design-cmb305-synovial\" target=\"_blank\">announcement </a>that it will initiate a Phase 3 study assessing cancer vaccine candidate CMB305 in NY-ESO-1-positive synovial sarcoma. Investors appear disappointed over the potential timeline of the study, expected to start in mid-2018, and its potential effect on the company's marketing applications.</li><li>The only other obvious bad news was a downgrade to Neutral by Wells Fargo on Monday but this does not normally account for a selloff of this severity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301329-immune-design-launch-pivotal-study-cancer-vaccine-candidate-cmb305-shares-ahead-9-percent\" target=\"_blank\">Immune Design to launch pivotal study for cancer vaccine candidate CMB305; shares ahead 9% after hours</a> (Oct. 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301562-wells-downgrade-weighs-immune-design-shares-13-percent\" target=\"_blank\">Wells downgrade weighs on Immune Design; shares down 13%</a> (Oct. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301912\" data-linked=\"Immune Design continues freefall, down 20%\" data-tweet=\"$IMDZ - Immune Design continues freefall, down 20% https://seekingalpha.com/news/3301912-immune-design-continues-freefall-down-20?source=tweet\" data-url=\"https://seekingalpha.com/news/3301912-immune-design-continues-freefall-down-20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301908\" data-ts=\"1508353244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBUU\" target=\"_blank\">MBUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301908-boating-stocks-rally-on-positive-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boating stocks rally on positive data</a></h4><ul><li>Boating stocks perk up after <a href=\"http://www.statisticalsurveys.com/index.aspx\" target=\"_blank\">data</a> on September sales comes in ahead of expectations.</li><li>Though the hurricanes striking Florida and Texas led to a 4.8% drop in retail boat sales during the month, B. Riley tells Bloomberg that some underlying trends in the sector look solid</li><li>Gainers on the day include Malibu Boats (<a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a> <font color='green'>+1.8%</font>), Brunswick (<a href='https://seekingalpha.com/symbol/BC' title='Brunswick Corporation'>BC</a> <font color='green'>+1.1%</font>), MasterCraft (<a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a> <font color='green'>+1.8%</font>), MarineMaz (<a href='https://seekingalpha.com/symbol/HZO' title='MarineMax Inc.'>HZO</a> <font color='green'>+2%</font>) and Marine Products (<a href='https://seekingalpha.com/symbol/MPX' title='Marine Products Corporation'>MPX</a> <font color='green'>+3.1%</font>),</li></ul><div class=\"tiny-share-widget\" data-id=\"3301908\" data-linked=\"Boating stocks rally on positive data\" data-tweet=\"$MBUU $MBUU $BC - Boating stocks rally on positive data https://seekingalpha.com/news/3301908-boating-stocks-rally-on-positive-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3301908-boating-stocks-rally-on-positive-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301905\" data-ts=\"1508352967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301905-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NSYS' title='Nortech Systems Incorporated'>NSYS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/TSRI' title='TSR, Inc.'>TSRI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MOBL' title='MobileIron, Inc.'>MOBL</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301905\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$VERI $CREE $NSYS - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3301905-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301905-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301904\" data-ts=\"1508352545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301904-rio-tintominus-4-african-scandal-continues-to-bite\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto -4% as African scandal continues to bite</a></h4><ul>     <li>Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-3.8%</font>) plunges nearly 4% as the <a href=\"https://seekingalpha.com/news/3301666-sec-charges-rio-tinto-two-former-top-execs-fraud\" target=\"_blank\">SEC charged</a> that the miner and its former CEO and CFO tried to hide a multibillion-dollar business failure by inflating the value of coal assets in Mozambique.</li>     <li>Separately, Rio agreed to pay &pound;27M ($36M) to settle claims by the U.K. Financial Conduct Authority over the Mozambique dealings.</li><li>RBC analyst Tyler Broda expects a settlement with the SEC and thinks the share price <a href=\"https://www.ft.com/content/1028519c-b405-11e7-aa26-bb002965bce8?mhq5j=e5\" target=\"_blank\">likely will not suffer severe harm</a> five years after the alleged activities, \"but it will probably cause more noise around Rio&rsquo;s corporate culture, especially on the back of the Simandou [Guinea] bribery allegations from last year.&rdquo;</li><li>The two African misadventures also threaten to cast a shadow over the eight-year tenure of Chairman Jan du Plessis, who is due to step down next year.</li>     <li>The SEC says it will seek to bar former CEO&nbsp;Tom Albanese and former CFO&nbsp;Guy Elliott from serving as officers or directors of a public company; the allegations today forced Elliott, to resign from the board of Royal Dutch Shell (<a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a>, <a href='https://seekingalpha.com/symbol/RDS.B' title='Royal Dutch Shell plc'>RDS.B</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301904\" data-linked=\"Rio Tinto -4% as African scandal continues to bite\" data-tweet=\"$RIO $RIO $RDS.A - Rio Tinto -4% as African scandal continues to bite https://seekingalpha.com/news/3301904-rio-tintominus-4-african-scandal-continues-to-bite?source=tweet\" data-url=\"https://seekingalpha.com/news/3301904-rio-tintominus-4-african-scandal-continues-to-bite\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301903\" data-ts=\"1508351709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301903-california-looking-to-pull-cardinal-health-license-over-opioids-stat-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California looking to pull Cardinal Health license over opioids - Stat News</a></h4><ul><li>At issue, <a href=\"https://www.statnews.com/pharmalot/2017/10/18/california-cardinal-health-opioids/\" target=\"_blank\">according to the report</a>, is Cardinal Health's (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>) failure to disclose unusual sales of an opioid painkiller and three other tightly regulated medicines from its Valencia, CA outpost to Pacific Plaza Pharmacy.</li><li>Should that Valencia license be revoked, Cardinal does have eight other locations in the state from which to do business.</li><li>Shares were nicely higher prior to the report, but now&nbsp;<font color='red'>down 0.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301903\" data-linked=\"California looking to pull Cardinal Health license over opioids - Stat News\" data-tweet=\"$CAH - California looking to pull Cardinal Health license over opioids - Stat News https://seekingalpha.com/news/3301903-california-looking-to-pull-cardinal-health-license-over-opioids-stat-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3301903-california-looking-to-pull-cardinal-health-license-over-opioids-stat-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301898\" data-ts=\"1508351019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBNK\" target=\"_blank\">GBNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301898-guaranty-bancorp-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guaranty Bancorp beats by $0.03, beats on revenue</a></h4><ul><li>Guaranty Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/GBNK' title='Guaranty Bancorp'>GBNK</a>): Q3 EPS of $0.40 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $37.46M (+36.5% Y/Y) <font color='green'>beats by $0.69M</font>.</li><li>Shares <font color='green'>+1.08%</font>.</li><li><a href='https://seekingalpha.com/pr/16972682-guaranty-bancorp-announces-third-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301898\" data-linked=\"Guaranty Bancorp beats by $0.03, beats on revenue\" data-tweet=\"$GBNK - Guaranty Bancorp beats by $0.03, beats on revenue https://seekingalpha.com/news/3301898-guaranty-bancorp-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301898-guaranty-bancorp-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301897\" data-ts=\"1508350642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301897-ulta-beauty-tracks-back-after-piper-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ulta Beauty tracks back after Piper downgrade</a></h4><ul><li>Shares of Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='red'>-1.5%</font>) swing lower after Piper Jaffray downgrades the retailer to Neutral from Overweight.</li><li>The firm relies partially on its proprietary survey on teenager preferences in making its call.</li><li>Piper slashes its price target on ULTA to $210 from $260.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300660-teenagers-pick-favorite-brands\" target=\"_blank\">Teenagers pick their favori</a><a href=\"https://seekingalpha.com/news/3300660-teenagers-pick-favorite-brands\" target=\"_blank\">te brands</a> (Oct. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301897\" data-linked=\"Ulta Beauty tracks back after Piper downgrade\" data-tweet=\"$ULTA - Ulta Beauty tracks back after Piper downgrade https://seekingalpha.com/news/3301897-ulta-beauty-tracks-back-after-piper-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3301897-ulta-beauty-tracks-back-after-piper-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301896\" data-ts=\"1508350352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTCS\" target=\"_blank\">BTCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301896-bitcoin-recovers-much-of-post-cftc-tumble\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin recovers much of post-CFTC tumble</a></h4><ul><li>The cryptocurrency was&nbsp;<font color='red'>down nearly 10%&nbsp;</font>earlier after the CFTC last night <a href=\"https://www.bloomberg.com/news/articles/2017-10-18/bitcoin-dips-most-in-month-on-oversight-fear-that-s-not-a-lot\" target=\"_blank\">suggested \"tokens\" used</a> in initial coin offerings may be subject to agency regulation. The SEC, of course, two years ago said much the same thing about ICOs.</li><li>Bitcoin fell to as low as $5,110, but at last check was at $5,374,&nbsp;<font color='red'>down 4%</font>&nbsp;on the session.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301896\" data-linked=\"Bitcoin recovers much of post-CFTC tumble\" data-tweet=\"$BTCS $BTCS $BTSC - Bitcoin recovers much of post-CFTC tumble https://seekingalpha.com/news/3301896-bitcoin-recovers-much-of-post-cftc-tumble?source=tweet\" data-url=\"https://seekingalpha.com/news/3301896-bitcoin-recovers-much-of-post-cftc-tumble\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301892\" data-ts=\"1508349696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301892-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KMG' title='KMG Chemicals, Inc.'>KMG</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301892\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$CGG-OLD $WLB $HCR - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3301892-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301892-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301887\" data-ts=\"1508348565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301887-aytu-promoted-to-nasdaq-capital-market-effective-october-20-shares-up-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu promoted to Nasdaq Capital Market effective October 20; shares up 23%</a></h4><ul><li>Aytu BioScience (<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a> <font color='green'>+22.6%</font>) will be <a href=\"https://seekingalpha.com/pr/16971952-aytu-bioscience-announces-uplisting-nasdaq-capital-market\" target=\"_blank\">uplisted </a>to the Nasdaq Capital Market effective Friday, October 20. The trading symbol will remain unchanged.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301887\" data-linked=\"Aytu promoted to Nasdaq Capital Market effective October 20; shares up 23%\" data-tweet=\"$AYTU - Aytu promoted to Nasdaq Capital Market effective October 20; shares up 23% https://seekingalpha.com/news/3301887-aytu-promoted-to-nasdaq-capital-market-effective-october-20-shares-up-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3301887-aytu-promoted-to-nasdaq-capital-market-effective-october-20-shares-up-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301885\" data-ts=\"1508348428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MD\" target=\"_blank\">MD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301885-mednax-buys-houston-based-radiology-practice-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEDNAX buys Houston-based radiology practice; shares up 1%</a></h4><ul><li>MEDNAX (<a href='https://seekingalpha.com/symbol/MD' title='Mednax, Inc.'>MD</a> <font color='green'>+1.3%</font>) <a href=\"https://seekingalpha.com/pr/16971694-mednax-announces-acquisition-leading-texas-radiology-practice\" target=\"_blank\">acquires </a>Houston, TX-based Synergy Radiology Associates for an undisclosed sum of cash and stock. The company says the 90-doctor practice will be immediately accretive to earnings. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301885\" data-linked=\"MEDNAX buys Houston-based radiology practice; shares up 1%\" data-tweet=\"$MD - MEDNAX buys Houston-based radiology practice; shares up 1% https://seekingalpha.com/news/3301885-mednax-buys-houston-based-radiology-practice-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3301885-mednax-buys-houston-based-radiology-practice-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301880\" data-ts=\"1508347770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301880-financials-top-5-gainers-losers-of-1-30-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:30 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+8%</font>.<a href='https://seekingalpha.com/symbol/NSM' title='Nationstar Mortgage Holdings'>NSM</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CTBI' title='Community Trust Bancorp, Inc.'>CTBI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/AIZ' title='Assurant, Inc.'>AIZ</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/VIRT' title='Virtu Financial, Inc.'>VIRT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AAME' title='Atlantic American Corporation'>AAME</a> <font color='red'>-6%</font>. RFT <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301880\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:30 PM\" data-tweet=\"$JP $CCCR-OLD $NSM - Financials - Top 5 Gainers / Losers as of 1:30 PM https://seekingalpha.com/news/3301880-financials-top-5-gainers-losers-of-1-30-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301880-financials-top-5-gainers-losers-of-1-30-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301878\" data-ts=\"1508347092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOVN\" target=\"_blank\">NOVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301878-novan-secures-rights-to-nitric-oxide-for-certain-oncovirus-applications-from-know-bio-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novan secures rights to nitric oxide for certain oncovirus applications from KNOW Bio; shares up 2%</a></h4><ul><li>Novan (<a href='https://seekingalpha.com/symbol/NOVN' title='Novan'>NOVN</a> <font color='green'>+1.6%</font>) inks an <a href=\"https://seekingalpha.com/pr/16971772-novan-acquires-ip-rights-treat-viral-malignancies-nitric-oxide\" target=\"_blank\">agreement </a>with privately held KNOW Bio, LLC for exclusive global rights to nitric oxide for certain oncovirus applications. It plans to explore nitric oxide's antiviral activity against neoplasias (abnormal growths) and carcinomas caused by high-risk human papillomavirus &#40;HPV&#41;.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301878\" data-linked=\"Novan secures rights to nitric oxide for certain oncovirus applications from KNOW Bio; shares up 2%\" data-tweet=\"$NOVN - Novan secures rights to nitric oxide for certain oncovirus applications from KNOW Bio; shares up 2% https://seekingalpha.com/news/3301878-novan-secures-rights-to-nitric-oxide-for-certain-oncovirus-applications-from-know-bio-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301878-novan-secures-rights-to-nitric-oxide-for-certain-oncovirus-applications-from-know-bio-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301873\" data-ts=\"1508346288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301873-biomarin-updates-investors-r-and-d-day-cautious-revenue-outlook-pressures-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioMarin updates investors at R&amp;D day; cautious revenue outlook pressures shares, down 3%</a></h4><ul><li>BioMarin Pharmaceutical (<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color='red'>-3%</font>) <a href=\"https://seekingalpha.com/pr/16972589-biomarin-highlights-breadth-innovative-development-pipeline-r-and-d-day-october-18th-new-york\" target=\"_blank\">updated </a>investors today at its R&amp;D event in New York City. Key developments:</li><li>FDA decision on PKU med pegvaliase expected in H1 2018. European marketing application to be filed in Q1 2018.</li><li>BMN 290, a selective chromatin modulator, has been selected for development to treat Friedreich's Ataxia. IND on tap in H2 2018. It is a second-generation version of the compound acquired from Repligen.</li><li>FDA has signed off on the IND for gene therapy BMN 270 for hemophilia A, including the protocol for a Phase 3 study. The protocol for a second Phase 3 assessing a lower dose has been submitted for review. The global Phase 3 program will be initiated this quarter. The generic name will be valoctocogene roxaparvovec.</li><li>Company's gene therapy manufacturing facilities capable of supporting 2,000 patients per year.</li><li>Updated data from Phase 2 study of vosoritide showed a sustained increase on growth velocity over 30 months of treatment in 10 subjects.</li><li><strong>2017 guidance update</strong>: slowing of government purchases in Brazil may impact revenue guidance. If orders are placed as expected, revenue should be at the midpoint, but may drop to the low end if they continue to slow. Non-GAAP earnings are still expected to be in the mid-to-high range. Guidance as of August 2: Revenues: $1.285B - 1.335B; Non-GAAP Income: $30M - 70M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301873\" data-linked=\"BioMarin updates investors at R&amp;D day; cautious revenue outlook pressures shares, down 3%\" data-tweet=\"$BMRN - BioMarin updates investors at R&amp;D day; cautious revenue outlook pressures shares, down 3% https://seekingalpha.com/news/3301873-biomarin-updates-investors-r-and-d-day-cautious-revenue-outlook-pressures-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3301873-biomarin-updates-investors-r-and-d-day-cautious-revenue-outlook-pressures-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301870\" data-ts=\"1508345417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301870-jd-com-makes-singles-day-moves-in-teaming-tencent-wal-mart\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com makes Singles Day moves in teaming with Tencent, Wal-Mart</a></h4><ul>   <li>Ahead of China's biggest shopping day of the year, JD.com (<a href=\"http://seekingalpha.com/symbol/JD\" target=\"_blank\">JD</a> <font color='green'>+2.9%</font>) is making its move against sales leader Alibaba (<a href=\"http://seekingalpha.com/symbol/BABA\" target=\"_blank\">BABA</a> <font color='green'>+1.8%</font>), with a <a href=\"https://seekingalpha.com/pr/16971578-jd-tencent-change-game-big-data-marketing\" target=\"_blank\">data deal it's entering with Tencent</a> (<a href=\"http://seekingalpha.com/symbol/TCEHY\" target=\"_blank\">TCEHY</a> <font color='green'>+0.7%</font>) as well as a partnership with Wal-Mart (<a href=\"http://seekingalpha.com/symbol/WMT\" target=\"_blank\">WMT</a> <font color='green'>+0.4%</font>).</li>    <li>Singles Day arrives Nov. 11, marking the world's biggest day for online shopping; last year, Alibaba set a Singles Day record with 120.7B yuan (about $17.8B) in gross merchandise moved.</li>    <li>The \"JD-Tencent Retail Marketing Solution\" will combine purchasing history with data on the 900M users of WeChat to get greater insight into purchasing decisions. It builds on a partnership announced in late 2015 where the two combined on mobile marketing solutions.</li>    <li>It also gives online discounts to WeChat Pay users who are shopping in physical stores.</li>    <li>Meanwhile, JD and Wal-Mart (one of JD.com's top shareholders) will <a href=\"https://asia.nikkei.com/Business/Consumers/JD.com-builds-coalition-to-challenge-e-commerce-leader-Alibaba\" target=\"_blank\">merge membership systems in China</a> to combine discounts and consumer benefits, and allow JD to fulfill customer orders using Wal-Mart's inventory. Wal-Mart has about 400 stores in China.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301870\" data-linked=\"JD.com makes Singles Day moves in teaming with Tencent, Wal-Mart\" data-tweet=\"$JD $JD $BABA - JD.com makes Singles Day moves in teaming with Tencent, Wal-Mart https://seekingalpha.com/news/3301870-jd-com-makes-singles-day-moves-in-teaming-tencent-wal-mart?source=tweet\" data-url=\"https://seekingalpha.com/news/3301870-jd-com-makes-singles-day-moves-in-teaming-tencent-wal-mart\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301869\" data-ts=\"1508345159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CP\" target=\"_blank\">CP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301869-two-year-high-for-canadian-pacific-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two-year high for Canadian Pacific after earnings</a></h4><ul>     <li>A confident tone from Canadian Pacific's (<a href='https://seekingalpha.com/symbol/CP' title='Canadian Pacific Railway Limited'>CP</a> <font color='green'>+5.8%</font>) management during the firm's earnings call is helping shares run to a two-year high.</li><li>Progress on the labor front was cited as well as some gains with pricing.</li>     <li>\"Pricing improved this quarter. Same-store price planned towards the high end of 2.5% to 3% range. And I can tell you we&rsquo;re optimistic that pricing could present upside as we look forward,\" updated CP's John Brooks.</li><li>Capital allocation was also a topic during the call. Execs noted the $575M in free cash flow generated YTD is helping the company to buy back shares.</li><li><a href=\"https://seekingalpha.com/article/4114145-canadian-pacific-railways-cp-ceo-keith-creel-q3-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">Canadian Pacific earnings call transcript</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3301600-canadian-pacific-railway-beats-c-0_05\" target=\"_blank\">Canadian Pacific Railway beats by C$0.05</a> (Oct. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301613-canadian-pacific-keeps-operating-expenses-check\" target=\"_blank\">Canadian Pacific keeps operating expenses in check</a> (Oct. 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301869\" data-linked=\"Two-year high for Canadian Pacific after earnings\" data-tweet=\"$CP - Two-year high for Canadian Pacific after earnings https://seekingalpha.com/news/3301869-two-year-high-for-canadian-pacific-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3301869-two-year-high-for-canadian-pacific-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301868\" data-ts=\"1508345136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECA\" target=\"_blank\">ECA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301868-encanaplus-4-on-glowing-five-year-projections\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Encana +4% on glowing five-year projections</a></h4><ul>     <li>Encana (<a href='https://seekingalpha.com/symbol/ECA' title='Encana Corporation'>ECA</a> <font color='green'>+4.4%</font>) says it expects to <a href=\"http://www.nasdaq.com/article/encana-updates-fiveyear-plan-20171018-00211\" target=\"_blank\">increase cash flow by ~25%/year</a> over the next five years, according to a <a href=\"http://www.encana.com/investors/presentations-events/\" target=\"_blank\">presentation slides</a> released for the company's investor day.</li>     <li>ECA forecasts cumulative free cash flow through 2022 will total ~$1.5B, assuming oil prices at $50/bbl, driven by a profit margin that expands to $16/bbl of production, up from ~$11/bbl currently.</li>     <li>\"Our updated five-year plan is better on every measure,\" says ECA&nbsp;President and CEO&nbsp;Doug Suttles. \"We are on track to deliver leading corporate returns, strong cash flow growth and substantial free cash flow, without any improvement in commodity prices.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3301868\" data-linked=\"Encana +4% on glowing five-year projections\" data-tweet=\"$ECA - Encana +4% on glowing five-year projections https://seekingalpha.com/news/3301868-encanaplus-4-on-glowing-five-year-projections?source=tweet\" data-url=\"https://seekingalpha.com/news/3301868-encanaplus-4-on-glowing-five-year-projections\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301867\" data-ts=\"1508344901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301867-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ISIG' title='Insignia Systems, Inc.'>ISIG</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-19%</font>. NEOT <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301867\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SPPI $OPTT $DRIO - Midday Gainers / Losers https://seekingalpha.com/news/3301867-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3301867-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301866\" data-ts=\"1508344849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INNV\" target=\"_blank\">INNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301866-innovus-pharmas-vesele-okd-in-canada-shares-ahead-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovus Pharma&#39;s Vesele OK&#39;d in Canada; shares ahead 7%</a></h4><ul><li>Health Canada <a href=\"https://seekingalpha.com/pr/16971661-innovus-pharma-receives-approval-health-canada-vesele-natural-health-product\" target=\"_blank\">approves </a>Innovus Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/INNV' title='Innovus Pharmaceuticals, Inc.'>OTCQB:INNV</a> <font color='green'>+6.7%</font>) Vesele, an over-the-counter natural health product to treat sexual dysfunction. The company plans to launch the product directly through its Beyond Human sales and marketing platform and through other sales channels.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301866\" data-linked=\"Innovus Pharma&#39;s Vesele OK&#39;d in Canada; shares ahead 7%\" data-tweet=\"$INNV - Innovus Pharma&#39;s Vesele OK&#39;d in Canada; shares ahead 7% https://seekingalpha.com/news/3301866-innovus-pharmas-vesele-okd-in-canada-shares-ahead-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3301866-innovus-pharmas-vesele-okd-in-canada-shares-ahead-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301861\" data-ts=\"1508343847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPC\" target=\"_blank\">EPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301861-52-week-low-for-edgewell-personal-care\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">52-week low for Edgewell Personal Care</a></h4><ul><li>Shares of Edgewell Personal Care (<a href='https://seekingalpha.com/symbol/EPC' title='Edgewell Personal Care'>EPC</a> <font color='red'>-2.3%</font>) are under pressure after <a href=\"https://www.iriworldwide.com/en-US/\" target=\"_blank\">IRI data</a> shows a surprising 8% drop in razor blade sales for a four-week period ending on October 8.</li><li>Edgewell lost some market share during the period to its competitors.</li><li>Edgewell traded at a 52-week low of $68.28 earlier.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301861\" data-linked=\"52-week low for Edgewell Personal Care\" data-tweet=\"$EPC - 52-week low for Edgewell Personal Care https://seekingalpha.com/news/3301861-52-week-low-for-edgewell-personal-care?source=tweet\" data-url=\"https://seekingalpha.com/news/3301861-52-week-low-for-edgewell-personal-care\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301860\" data-ts=\"1508343827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPTT\" target=\"_blank\">OPTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301860-ocean-power-techplus-40-after-patent-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocean Power Tech +40% after patent approval</a></h4><ul>     <li>Ocean Power Technologies (<a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='green'>+41.7%</font>) skyrockets after the company is <a href=\"http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PTXT&amp;s1=9,790,913&amp;OS=9,790,913&amp;RS=9,790,913\" target=\"_blank\">granted a patent</a> for a wave energy system that harnesses free power from the ocean.</li>     <li>OPTT's \"invention is directed to a novel [wave energy conversion] technology which may be referred to as pitch driven WEC technology and which, in its implementation, eliminates the need of springs to overcome gravitational forces.\"</li><li>The company has not yet issued a press release discussing the patent award.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301860\" data-linked=\"Ocean Power Tech +40% after patent approval\" data-tweet=\"$OPTT - Ocean Power Tech +40% after patent approval https://seekingalpha.com/news/3301860-ocean-power-techplus-40-after-patent-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3301860-ocean-power-techplus-40-after-patent-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301859\" data-ts=\"1508343776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDUS\" target=\"_blank\">RDUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301859-radius-healths-elacestrant-fast-trackd-for-certain-type-of-breast-cancer-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Radius Health&#39;s elacestrant Fast Track&#39;d for certain type of breast cancer; shares up 2%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16972207-radius-health-receives-fda-fast-track-designation-elacestrant-rad1901\" target=\"_blank\">designates </a>Radius Health's (<a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a> <font color='green'>+1.8%</font>) elacestrant for Fast Track review for the treatment of patients with ER+/HER2- advanced/metastatic breast cancer.</li><li>A Phase 2 study, which may be sufficient to support a marketing application, will commence in Q1 2018.</li><li>Elacestrant (RAD-1901) is an oral selective estrogen receptor down-regulator/degrader.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301859\" data-linked=\"Radius Health&#39;s elacestrant Fast Track&#39;d for certain type of breast cancer; shares up 2%\" data-tweet=\"$RDUS - Radius Health&#39;s elacestrant Fast Track&#39;d for certain type of breast cancer; shares up 2% https://seekingalpha.com/news/3301859-radius-healths-elacestrant-fast-trackd-for-certain-type-of-breast-cancer-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3301859-radius-healths-elacestrant-fast-trackd-for-certain-type-of-breast-cancer-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301855\" data-ts=\"1508342673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301855-shire-feels-allergans-restasis-patent-pain-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire feels Allergan&#39;s Restasis patent pain, shares down 3%</a></h4><ul><li>The RESTASIS patent invalidation-stoked selling in Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-4.7%</font>) has spread to Shire plc (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='red'>-3.6%</font>) as investors perceive generic encroachment on its Xiidra (lifitegrast ophthalmic solution) franchise.</li><li>The selling appears overdone considering that Shire's ophthalmology franchise accounted for only ~2% of Q2 product sales ($57.4M/2,375.1M).</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301249-u-s-court-invalidates-allergans-restasis-patents-shares-5-percent\" target=\"_blank\">U.S. court invalidates Allergan's Restasis patents; shares down 5%</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301855\" data-linked=\"Shire feels Allergan&#39;s Restasis patent pain, shares down 3%\" data-tweet=\"$AGN $AGN $SHPG - Shire feels Allergan&#39;s Restasis patent pain, shares down 3% https://seekingalpha.com/news/3301855-shire-feels-allergans-restasis-patent-pain-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3301855-shire-feels-allergans-restasis-patent-pain-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301854\" data-ts=\"1508342491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301854-investors-lap-up-chinese-consumer-finance-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors lap up Chinese consumer finance IPO</a></h4><ul><li>Backed by Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>), Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian, Inc.'>QD</a>) is a provider <a href=\"https://www.cnbc.com/2017/10/18/qudian-spikes-more-than-40-percent-in-ipo.html\" target=\"_blank\">of short-term micro loans</a> to Chinese consumers through its mobile app or online.</li><li>It priced its 37.5M ADS IPO at $24 each vs. the expected range of $19-$22, giving the company a valuation of nearly $8B.</li><li>In early action, shares are now trading hands at $34,&nbsp;<font color='green'>up 41.7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301854\" data-linked=\"Investors lap up Chinese consumer finance IPO\" data-tweet=\"$BABA $BABA $QD - Investors lap up Chinese consumer finance IPO https://seekingalpha.com/news/3301854-investors-lap-up-chinese-consumer-finance-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/3301854-investors-lap-up-chinese-consumer-finance-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301853\" data-ts=\"1508342458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301853-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> SCSS <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/LFVN' title='LifeVantage Corporation'>LFVN</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301853\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SNBR $LFVN $LBIX-OLD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3301853-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3301853-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301846\" data-ts=\"1508341291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301846-cfda-accepts-fibrogens-marketing-application-for-anemia-med-roxadustat-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CFDA accepts FibroGen&#39;s marketing application for anemia med roxadustat; shares up 1%</a></h4><ul><li>The China Food and Drug Administration &#40;CFDA&#41; <a href=\"https://seekingalpha.com/pr/16971760-fibrogen-announces-acceptance-china-fda-roxadustat-new-drug-application-nda-treatment-anemia\" target=\"_blank\">accepts for review</a> FibroGen's (<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a> <font color='green'>+1.3%</font>) marketing application seeking approval for roxadustat to treat anemia in patients with chronic kidney disease regardless of their dialysis status.</li><li>The filing triggers a $15M milestone payment from collaboration partner AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='red'>-0.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3301846\" data-linked=\"CFDA accepts FibroGen&#39;s marketing application for anemia med roxadustat; shares up 1%\" data-tweet=\"$FGEN $FGEN $AZN - CFDA accepts FibroGen&#39;s marketing application for anemia med roxadustat; shares up 1% https://seekingalpha.com/news/3301846-cfda-accepts-fibrogens-marketing-application-for-anemia-med-roxadustat-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3301846-cfda-accepts-fibrogens-marketing-application-for-anemia-med-roxadustat-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301844\" data-ts=\"1508338919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301844-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-26%</font>. NEOT <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301844\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$DRIO $SPPI $RXDX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3301844-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3301844-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301842\" data-ts=\"1508338476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301842-transoceanminus-4-after-signing-new-rig-contract-75-dayrate-discount\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean -4% after signing new rig contract at 75% dayrate discount</a></h4><ul>     <li>Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-3.8%</font>) sinks despite <a href=\"https://globenewswire.com/news-release/2017/10/17/1148925/0/en/Transocean-Ltd-Announces-Two-Year-Contract-for-Ultra-Deepwater-Drillship-Deepwater-Invictus.html\" target=\"_blank\">signing a new two-year contract</a> for the <em>Deepwater Invictus</em> ultra-deepwater drillship with three one-year priced options.</li>     <li>The rig&rsquo;s $106M of revenue for two years of work calculates to a $145K dayrate, a <a href=\"https://seekingalpha.com/article/4114259-transocean-gets-2-year-job-bhp-agrees-75-percent-discount-previous-rate\" target=\"_blank\">75% reduction</a> from the current $592K - a great deal for BHP Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-1.4%</font>), which secures a modern rig built in 2014 for a very cheap price - further evidence of the dismal state of the offshore drilling market.</li>     <li>Bloomberg also published a story today describing RIG's <a href=\"https://www.bloomberg.com/news/articles/2017-10-18/oil-s-biggest-rigs-get-sent-to-junkyard-as-daily-losses-mount\" target=\"_blank\">retirement of six floating rigs</a> that will add up to a $1.4B writeoff as a signal of \"just how bleak the future looks for deepwater drilling.\"</li>     <li>Offshore drilling rig operators junked more rigs during Q3 than have ever been trashed in a 90-day stretch, according to the report.</li>     <li>&ldquo;Deepwater is going to be playing a much-reduced role on the global oil supply stage relative to what the industry expected as recently as three years ago,&rdquo; says FBR&nbsp;analyst Thomas Curran.</li><li>Also: <a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a> <font color='red'>-3.5%</font>, <a href='https://seekingalpha.com/symbol/DO' title='Diamond Offshore Drilling Inc.'>DO</a> <font color='red'>-0.7%</font>, <a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a> <font color='red'>-0.5%</font>, <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-8.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301842\" data-linked=\"Transocean -4% after signing new rig contract at 75% dayrate discount\" data-tweet=\"$RIG $RIG $BHP - Transocean -4% after signing new rig contract at 75% dayrate discount https://seekingalpha.com/news/3301842-transoceanminus-4-after-signing-new-rig-contract-75-dayrate-discount?source=tweet\" data-url=\"https://seekingalpha.com/news/3301842-transoceanminus-4-after-signing-new-rig-contract-75-dayrate-discount\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301841\" data-ts=\"1508338472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADTN\" target=\"_blank\">ADTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301841-adtranminus-4_4-after-posting-mixed-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adtran -4.4% after posting mixed Q3 results</a></h4><ul>   <li>The stock opened at a 3.5-year high of $25.10, but Adtran (NASDAQ:<a href='https://seekingalpha.com/symbol/ADTN' title='ADTRAN, Inc.'>ADTN</a>) quickly dropped and has <font color='red'>declined 4.4%</font> after posting <a href=\"https://seekingalpha.com/news/3301675-adtran-beats-0_10-misses-revenue\" target=\"_blank\">Q3 earnings</a> where profits beat expectations but revenues fell just short of consensus.</li>    <li>Net income rose to $15.9M from a year-ago $12.4M; non-GAAP EPS rose 42% to $0.37.</li>    <li>Sales breakout: Products, $145.5M (up 6.7%); Services, $39.6M (up 21.6%).</li>    <li>We continued to see strong sales in our domestic ultra-broadband solutions and services, which have more than doubled from the same period last year,\" said CEO Tom Stanton. \"Total company revenues grew by 10% compared to the same period last year as a result of strength in both our Network Solutions segment and a record performance in our services revenues, which again grew at a double-digit pace.</li>    <li><a href=\"https://seekingalpha.com/pr/16971548-adtran-inc-reports-28-percent-increase-earnings-third-quarter-2017-declares-quarterly-cash\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3301841\" data-linked=\"Adtran -4.4% after posting mixed Q3 results\" data-tweet=\"$ADTN - Adtran -4.4% after posting mixed Q3 results https://seekingalpha.com/news/3301841-adtranminus-4_4-after-posting-mixed-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3301841-adtranminus-4_4-after-posting-mixed-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301836\" data-ts=\"1508338112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRIO\" target=\"_blank\">DRIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301836-dariohealth-up-57-on-ce-mark-for-glucose-monitor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DarioHealth up 57% on CE Mark for glucose monitor</a></h4><ul><li>Thinly traded nano cap DarioHealth (<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color='green'>+56.7%</font>) is up on whopping 152x surge in volume in response to <a href=\"https://seekingalpha.com/pr/16971880-dariohealth-gains-ce-mark-iphone-7-iphone-8-smart-glucose-meter\" target=\"_blank\">CE Mark certification</a> for its Dario Blood Glucose Monitoring System that can be used with the latest Apple devices, including the iPhone 8. It can be used with either a 3.5 mm headphone jack or Lightning connector.</li><li>CEO Erez Raphael says, \"We've been working tirelessly to bring forth a solution that would meet the rigorous standards required to achieve the CE Mark. We are proud that our organization worked with agility to ensure connectivity to the latest Apple devices. This significant milestone will allow us to open to a whole new market segment and re-engage with former Dario users who now have the newest Apple devices. The actual Lighting-enabled prototype has been ready for a long time, and the CE Mark is just the beginning. We will continue to support our users around the world and, to that end, have begun the formal process with regulatory agencies in the&nbsp;U.S.,&nbsp;Canada, and&nbsp;Australia.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3301836\" data-linked=\"DarioHealth up 57% on CE Mark for glucose monitor\" data-tweet=\"$DRIO - DarioHealth up 57% on CE Mark for glucose monitor https://seekingalpha.com/news/3301836-dariohealth-up-57-on-ce-mark-for-glucose-monitor?source=tweet\" data-url=\"https://seekingalpha.com/news/3301836-dariohealth-up-57-on-ce-mark-for-glucose-monitor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301827\" data-ts=\"1508337031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301827-mannkind-nabs-european-patent-covering-afrezza-system-investors-unmoved-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind nabs European patent covering Afrezza system; investors unmoved, shares down 7%</a></h4><ul><li>The European Patent Office issues a <a href=\"https://data.epo.org/publication-server/pdf-document?pn=2570147&amp;ki=B1&amp;cc=EP\" target=\"_blank\">new patent</a> protecting MannKind's (<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='red'>-7.4%</font>) dry powder <a href=\"http://www.mannkindcorp.com/research-development/tech-platforms/oral-inhalers/\" target=\"_blank\">inhaler device</a> used to deliver fast-acting insulin Afrezza. The patent covers the drug delivery device, cartridges and dry powder formulations.</li><li>Shares have lost ~37% of their value since touching $6.96 on October 10, although the stock ran up almost four-fold beforehand.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301827\" data-linked=\"MannKind nabs European patent covering Afrezza system; investors unmoved, shares down 7%\" data-tweet=\"$MNKD - MannKind nabs European patent covering Afrezza system; investors unmoved, shares down 7% https://seekingalpha.com/news/3301827-mannkind-nabs-european-patent-covering-afrezza-system-investors-unmoved-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3301827-mannkind-nabs-european-patent-covering-afrezza-system-investors-unmoved-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301829\" data-ts=\"1508337029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301829-eia-petroleum-inventories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Petroleum Inventories</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-5.7M</strong> barrels vs. -4.2M consensus, -2.8M last week.</li><li>Gasoline <strong>+0.9M</strong> barrels vs. +0.3M consensus, +2.5M last week.</li><li>Distillates <strong>+0.5M</strong> barrels vs. -1.5M consensus, -1.5M last week.</li><li>Futures&nbsp;<font color='green'>+0.69%</font>&nbsp;to $52.24.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3301829\" data-linked=\"EIA Petroleum Inventories\" data-tweet=\"$USO $OIL $UCO - EIA Petroleum Inventories https://seekingalpha.com/news/3301829-eia-petroleum-inventories?source=tweet\" data-url=\"https://seekingalpha.com/news/3301829-eia-petroleum-inventories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301825\" data-ts=\"1508336290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301825-supervalu-leads-grocery-sector-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supervalu leads grocery sector higher</a></h4><ul> <li>It's a super rally for Supervalu (<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a> <font color='green'>+9.3%</font>) after the company tops Q2 estimates and makes a strategic investment.</li> <li>The sizable profit beat turned in by Supervalu has helped sentiment across the jittery grocery store sector. In early trading, Natural Grocers by Vitamin Cottage (<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a> <font color='green'>+5.5%</font>), Smart &amp; Final Stores (<a href='https://seekingalpha.com/symbol/SFS' title='Smart & Final Stores'>SFS</a> <font color='green'>+3.7%</font>) and Ingles Markets (<a href='https://seekingalpha.com/symbol/IMKTA' title='Ingles Markets, Incorporated'>IMKTA</a> <font color='green'>+3.5%</font>) are making notable gains. Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='green'>+0.8%</font>) is also in positive territory.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3301719-supervalu-acquires-associated-grocers-florida\" target=\"_blank\">Supervalu acquires Associated Grocers of Florida</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301726-supervalus-q2-results\" target=\"_blank\">More on Supervalu's Q2 results</a> (Oct. 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301825\" data-linked=\"Supervalu leads grocery sector higher\" data-tweet=\"$SVU $SVU $NGVC - Supervalu leads grocery sector higher https://seekingalpha.com/news/3301825-supervalu-leads-grocery-sector-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3301825-supervalu-leads-grocery-sector-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301824\" data-ts=\"1508336083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGG-OLD\" target=\"_blank\">CGG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301824-cggplus-19-after-shareholder-vote-favors-restructuring-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CGG +19% after shareholder vote favors restructuring plan</a></h4><ul>     <li>CGG (<a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+19.6%</font>) surges in early trading after apparently obtaining a <a href=\"http://www.cgg.com/en/Investors/Press-Releases/2017/10/Financial-restructuring-plan-favorable-vote-by-long-standing-shareholders\" target=\"_blank\">favorable vote</a> by long-standing shareholders on its financial restructuring plan.</li>     <li>The French manufacturer of geophysical equipment, which filed for bankruptcy in France and the U.S. in June, is calling a vote on Oct. 31 regarding the restructuring plan, which it says should result in a favorable vote.</li>     <li>CGG has more than $3B in debt, and the restructuring calls for unsecured debt to be converted to equity, maturities on secured debt to be extended and $500M in new money to be raised.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301824\" data-linked=\"CGG +19% after shareholder vote favors restructuring plan\" data-tweet=\"$CGG-OLD - CGG +19% after shareholder vote favors restructuring plan https://seekingalpha.com/news/3301824-cggplus-19-after-shareholder-vote-favors-restructuring-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3301824-cggplus-19-after-shareholder-vote-favors-restructuring-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301817\" data-ts=\"1508334755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMAO\" target=\"_blank\">FMAO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301817-farmers-and-amp-merchants-bancorp-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Farmers &amp;amp; Merchants Bancorp EPS in-line, beats on revenue</a></h4><ul><li>Farmers &amp; Merchants Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/FMAO' title='Farmers & Merchants Bancorp Inc.'>FMAO</a>): Q3 EPS of $0.35 in-line.</li><li>Revenue of $9.2M (+8.4% Y/Y) <font color='green'>beats by $0.23M</font>.</li><li>Shares <font color='green'>+2.3%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16972323-farmers-and-merchants-bancorp-inc-reports-2017-third-quarter-year-date-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3301817\" data-linked=\"Farmers &amp;amp; Merchants Bancorp EPS in-line, beats on revenue\" data-tweet=\"$FMAO - Farmers &amp; Merchants Bancorp EPS in-line, beats on revenue https://seekingalpha.com/news/3301817-farmers-and-amp-merchants-bancorp-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3301817-farmers-and-amp-merchants-bancorp-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301807\" data-ts=\"1508333694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301807-akari-prices-ads-offering-5-shares-down-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari prices ADS offering at $5; shares down 24%</a></h4><ul><li>Akari Therapeutics (<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-23.8%</font>) <a href=\"https://seekingalpha.com/pr/16972221-akari-therapeutics-announces-pricing-public-offering-american-depositary-shares\" target=\"_blank\">prices </a>its public offering of 3.48M American Depositary Shares (ADSs) at $5 per ADS. Underwriters over-allotment is an additional 522K ADSs. Closing date is October 20.</li><li>Net proceeds will fund R&amp;D, working capital and general corporate purposes.</li><li>Yesterday's close was $6.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301807\" data-linked=\"Akari prices ADS offering at $5; shares down 24%\" data-tweet=\"$AKTX - Akari prices ADS offering at $5; shares down 24% https://seekingalpha.com/news/3301807-akari-prices-ads-offering-5-shares-down-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3301807-akari-prices-ads-offering-5-shares-down-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301802\" data-ts=\"1508333178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301802-longbow-upgrades-gopro-sharesplus-4_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Longbow upgrades GoPro; shares +4.2%</a></h4><ul><li>        Longbow upgrades GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>) from Neutral to Buy with a $13 price target based.</li><li>               Analyst Joe Wittine says the company &ldquo;stabilized the ship&rdquo; in early 2017 and improved execution, which isn&rsquo;t priced into the current valuation.&nbsp;</li><li>               Wittine also says the Google Clips-based selloff earlier this month was misguided because it&rsquo;s not a competing product.&nbsp;</li><li>               The analyst moves $30M of forecasted Q4 sales to Q1 due to planned inventory reductions. FY18 sales estimate now $1.5B with Q1 loss per share forecasted at $0.14 compared to the $0.23 loss consensus. &nbsp;&nbsp;</li><li>Source: Bloomberg First Word&nbsp;</li><li>GoPro shares are&nbsp;<font color='green'>up 4.23%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299370-gopro-shares-google-launch-event\" target=\"_blank\">GoPro shares down after Google launch event</a> (Oct. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299817-gopro-jpmorgan-dismisses-clips-concerns\" target=\"_blank\">GoPro up after JPMorgan dismisses Clips concerns</a> (Oct. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301802\" data-linked=\"Longbow upgrades GoPro; shares +4.2%\" data-tweet=\"$GPRO - Longbow upgrades GoPro; shares +4.2% https://seekingalpha.com/news/3301802-longbow-upgrades-gopro-sharesplus-4_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3301802-longbow-upgrades-gopro-sharesplus-4_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>86&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301799\" data-ts=\"1508333144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301799-abbvie-teams-up-harpoon-therapeutics-in-immuno-oncology-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% premarket</a></h4><ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on average volume on the heels of the <a href=\"https://seekingalpha.com/pr/16972048-arix-bioscience-notes-harpoon-therapeutics-immuno-oncology-collaboration-abbvie\" target=\"_blank\">announcement </a>that it has inked an immuno-oncology (I/O) research collaboration with Arix Bioscience unit Harpoon Therapeutics.</li><li>The partnership will leverage Harpoon's tri-specific T-cell activating construct (<a href=\"http://www.harpoontx.com/technology/\" target=\"_blank\">TriTAC</a>) platform with AbbVie's research-stage I/O targets aimed at developing novel cancer therapies.</li><li>Under the terms of the agreement, Harpoon will engineer and evaluate TriTAC molecules directed against selected cancer targets. AbbVie will have the right to pursue further development and commercialization. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301799\" data-linked=\"AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% premarket\" data-tweet=\"$ABBV - AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% premarket https://seekingalpha.com/news/3301799-abbvie-teams-up-harpoon-therapeutics-in-immuno-oncology-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301799-abbvie-teams-up-harpoon-therapeutics-in-immuno-oncology-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301798\" data-ts=\"1508333132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQIX\" target=\"_blank\">EQIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301798-equinixplus-1_8-barclays-lifts-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Equinix +1.8% as Barclays lifts to Overweight</a></h4><ul>   <li>Equinix (NASDAQ:<a href='https://seekingalpha.com/symbol/EQIX' title='Equinix, Inc.'>EQIX</a>) is <font color='green'>up 1.8%</font> premarket after a boost to Overweight at Barclays.</li>    <li>The firm raised its price target to $505 from $475, implying 9.4% upside from current pricing of $461.58. It had rated the data-center operator Equal Weight.</li>    <li>Meanwhile, UBS has launched coverage on Equinix with a Neutral rating.</li>    <li>The company is set to report earnings Nov. 1.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301798\" data-linked=\"Equinix +1.8% as Barclays lifts to Overweight\" data-tweet=\"$EQIX - Equinix +1.8% as Barclays lifts to Overweight https://seekingalpha.com/news/3301798-equinixplus-1_8-barclays-lifts-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3301798-equinixplus-1_8-barclays-lifts-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301795\" data-ts=\"1508332877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301795-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SSKN' title='STRATA Skin Sciences, Inc'>SSKN</a> <font color='green'>+38%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301637-strata-skin-sciences-inks-deal-aesthetic-medical-market-focused-group-purchasing-organization\" target=\"_blank\">deal</a> with aesthetic medical market-focused group purchasing organization.</li>     <li><a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+34%</font>&nbsp;as poziotinib <a href=\"https://seekingalpha.com/news/3301753-spectrum-pharmas-poziotinib-shows-encouraging-effect-treatment-resistant-lung-cancer-patients\" target=\"_blank\">shows</a> encouraging effect in treatment-resistant lung cancer patients in mid-stage study.</li>     <li><a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a> <font color='green'>+31%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a> <font color='green'>+22%</font>&nbsp;as entrectinib <a href=\"https://seekingalpha.com/news/3301759-ignytas-entrectinib-shows-78-percent-response-rate-certain-patients-advanced-lung-cancer\" target=\"_blank\">shows</a> 78% response rate in certain patients with advanced lung cancer.</li>     <li><a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a> <font color='green'>+15%</font>&nbsp;as USPTO has <a href=\"https://seekingalpha.com/news/3301770-benitec-pharma-nabs-u-s-patent-covering-rnai-agent-treat-hbv-infection-shares-9-percent\" target=\"_blank\">issued</a> it a new patent (No. 9,790,502) covering its RNA interference (RNAi) agent to treat hepatitis B virus &#40;HBV&#41; infection.</li>     <li><a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='green'>+10%</font>&nbsp;on buyback <a href=\"https://seekingalpha.com/news/3301619-hi-crush-partners-declares-0_15-dividend\" target=\"_blank\">program</a>.</li>     <li>NEOT <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301455-neothetics-evofem-merge\" target=\"_blank\">merger</a> with Evofem.</li>     <li><a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a> <font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16971805-lightbridge-receives-approval-key-patent-china-innovative-fuel-design\" target=\"_blank\">receiving</a> notice of allowance in China for key patent relating to innovative metallic fuel design.</li>     <li><a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+6%</font>.</li>     <li>ADHD <font color='green'>+6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301795\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$SSKN $SPPI $OPTT - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3301795-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3301795-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301789\" data-ts=\"1508332415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301789-alnylam-teams-up-vir-biotech-to-advance-rnai-therapeutics-to-treat-infectious-diseases-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam teams up with Vir Biotech to advance RNAi therapeutics to treat infectious diseases; shares up 1% premarket</a></h4><ul><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16971758-alnylam-vir-form-strategic-alliance-advance-rnai-therapeutics-infectious-diseases\" target=\"_blank\">announcement </a>of an exclusive licensing agreement with Vir Biotechnology aimed at developing and commercializing RNAi therapeutics for the treatment of infectious diseases, including hepatitis B virus &#40;HBV&#41; infection.</li><li>The companies will advance Alnylam's HBV program and initiate collaborative research to develop and advance up to four additional RNAi programs.</li><li>Alnylam intends to terminate development of Phase 1/2-stage ALN-HBV in favor of a new candidate, ALN-HBV02, which is based on its Enhanced Stabilization Chemistry-Plus (ESC+) GalNac conjugate technology.</li><li>Alnylam will be responsible for the IND filing and Vir will take over through proof-of-concept. The firms will co-fund the program through this point. Vir will be responsible to conduct and fund development through Phase 2. Alnylam will have the opportunity to opt into a profit-sharing arrangement prior to the start of Phase 3.</li><li>Vir will fund all R&amp;D costs related to the other four programs with Alnylam retaining a product-specific option to opt into a profit-sharing arrangement following proof-of-concept testing.</li><li>Under the terms of the agreement, Alnylam will receive an upfront payment comprised of cash and Vir common stock, milestones up to $1B and tiered royalties, should it decline its co-development and profit-sharing option on a per-product basis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301789\" data-linked=\"Alnylam teams up with Vir Biotech to advance RNAi therapeutics to treat infectious diseases; shares up 1% premarket\" data-tweet=\"$ALNY - Alnylam teams up with Vir Biotech to advance RNAi therapeutics to treat infectious diseases; shares up 1% premarket https://seekingalpha.com/news/3301789-alnylam-teams-up-vir-biotech-to-advance-rnai-therapeutics-to-treat-infectious-diseases-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301789-alnylam-teams-up-vir-biotech-to-advance-rnai-therapeutics-to-treat-infectious-diseases-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301787\" data-ts=\"1508332300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301787-eaminus-2_3-after-move-to-shutter-visceral-delay-star-wars-game\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EA -2.3% after move to shutter Visceral, delay &#39;Star Wars&#39; game</a></h4><ul>   <li>Electronic Arts (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>) is <font color='red'>down 2.3%</font> premarket after word that it's <a href=\"https://www.gamespot.com/articles/eas-star-wars-action-adventure-game-will-be-revamp/1100-6454142/\" target=\"_blank\">closing down its Visceral studio</a>, throwing a delay into plans for a new action-adventure set in the <i>Star Wars</i> universe.</li>    <li>That new single-player game (a \"story-based, linear adventure\") had been set to launch late in fiscal 2019, but the company will report a new time frame for it in the future after development moves to EA's Worldwide Studios team with leadership from Vancouver.</li>    <li>\"It has become clear that to deliver an experience that players will want to come back to and enjoy for a long time to come, we needed to pivot the design,\" the company <a href=\"https://www.ea.com/news/an-update-on-the-visceral-star-wars-project\" target=\"_blank\">says in a site update</a>.</li>    <li>Visceral started out as EA's Redwood Shores studio and has developed a wide number of games over nearly 20 years.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301787\" data-linked=\"EA -2.3% after move to shutter Visceral, delay &#39;Star Wars&#39; game\" data-tweet=\"$EA - EA -2.3% after move to shutter Visceral, delay &#39;Star Wars&#39; game https://seekingalpha.com/news/3301787-eaminus-2_3-after-move-to-shutter-visceral-delay-star-wars-game?source=tweet\" data-url=\"https://seekingalpha.com/news/3301787-eaminus-2_3-after-move-to-shutter-visceral-delay-star-wars-game\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301785\" data-ts=\"1508332119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301785-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a>&nbsp;<font color='red'>-23%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3301604-akari-therapeutics-readies-equity-offering-shares-10-percent-hours\" target=\"_blank\">announcing</a> proposed public offering of ADSs.</li><li><a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-15%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3301785\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$AKTX $SRAX - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3301785-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3301785-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301770\" data-ts=\"1508330963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNTC\" target=\"_blank\">BNTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301770-benitec-pharma-nabs-u-s-patent-covering-rnai-agent-to-treat-hbv-infection-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Benitec Pharma nabs U.S. patent covering RNAi agent to treat HBV infection; shares up 9% premarket</a></h4><ul><li>Thinly traded nano cap Benitec Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a>) perks up&nbsp;<font color='green'>9%</font>&nbsp;premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/16971819-u-s-patent-granted-benitec-hepatitis-b-program\" target=\"_blank\">announcement </a>that the USPTO has issued it a new patent (No. 9,790,502) covering its RNA interference (RNAi) agent to treat hepatitis B virus &#40;HBV&#41; infection.</li><li>The company's technology combines RNAi with gene therapy to permanently silence disease-causing genes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301770\" data-linked=\"Benitec Pharma nabs U.S. patent covering RNAi agent to treat HBV infection; shares up 9% premarket\" data-tweet=\"$BNTC - Benitec Pharma nabs U.S. patent covering RNAi agent to treat HBV infection; shares up 9% premarket https://seekingalpha.com/news/3301770-benitec-pharma-nabs-u-s-patent-covering-rnai-agent-to-treat-hbv-infection-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3301770-benitec-pharma-nabs-u-s-patent-covering-rnai-agent-to-treat-hbv-infection-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301766\" data-ts=\"1508330515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOX\" target=\"_blank\">BOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301766-box-announces-cloud-management-deal-fda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Box announces cloud management deal with the FDA</a></h4><ul><li>        Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) <a href=\"https://seekingalpha.com/pr/16971891-u-s-food-drug-administration-selects-box-cloud-content-management\" target=\"_blank\">announces</a> that the U.S. Food and Drug Administration selected the company&rsquo;s platform to modernize technical infrastructure and discover new ways to operate in the cloud.</li><li>               Box will improve third-party collaborations, create a central communication portal, streamline the IT setup, and provide added cybersecurity solutions.&nbsp;</li><li>               Box shares are&nbsp;<font color='green'>up 1.38%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3301766\" data-linked=\"Box announces cloud management deal with the FDA\" data-tweet=\"$BOX - Box announces cloud management deal with the FDA https://seekingalpha.com/news/3301766-box-announces-cloud-management-deal-fda?source=tweet\" data-url=\"https://seekingalpha.com/news/3301766-box-announces-cloud-management-deal-fda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301765\" data-ts=\"1508330317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301765-protalix-out-licenses-fabry-candidate-prxminus-102-to-chiesi-shares-ahead-38-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarket</a></h4><ul><li>Nano cap Protalix BioTherapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLX' title='Protalix BioTherapeutics, Inc'>PLX</a>) jumps&nbsp;<font color='green'>38%</font>&nbsp;premarket on robust volume in response to its ex-U.S. license and collaboration <a href=\"https://seekingalpha.com/pr/16971700-protalix-biotherapeutics-enters-exclusive-ex-us-partnership-chiesi-farmaceutici-development\" target=\"_blank\">agreement </a>with Chiesi Farmaceutici S.p.A. for PRX-102 for the treatment of Fabry disease.</li><li>Under the terms of the agreement, Protalix will receive $25M upfront, up to $25M for development costs (capped at $10M/yr), up to $320M in milestones and tiered royalties from 15 - 35% on net sales.</li><li>Chiesi receives exclusive rights to PLX-102 for all markets outside of the U.S.</li><li><a href=\"http://www.protalix.com/development-pipeline/prx-102-fabry-disease.asp\" target=\"_blank\">PRX-102</a>&nbsp;is chemically modified version of a recombinant therapeutic enzyme called alpha-galactosidase A.</li><li><a href=\"https://ghr.nlm.nih.gov/condition/fabry-disease\" target=\"_blank\">Fabry disease</a>&nbsp;is an inherited disorder caused by mutations in the gene that codes for alpha-galactosidase A. It is characterized by the buildup of Gb3 in the body's cells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3257539-protalix-bios-prxminus-102-shows-encouraging-effect-fabry-models-compared-enzyme-replacement\" target=\"_blank\">Protalix Bio's PRX-102 shows encouraging effect in Fabry models compared to enzyme replacement therapies; shares ahead 7% premarket</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3301765\" data-linked=\"Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarket\" data-tweet=\"$PLX - Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarket https://seekingalpha.com/news/3301765-protalix-out-licenses-fabry-candidate-prxminus-102-to-chiesi-shares-ahead-38-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301765-protalix-out-licenses-fabry-candidate-prxminus-102-to-chiesi-shares-ahead-38-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301759\" data-ts=\"1508329734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RXDX\" target=\"_blank\">RXDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301759-ignytas-entrectinib-shows-78-response-rate-in-certain-patients-advanced-lung-cancer-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ignyta&#39;s entrectinib shows 78% response rate in certain patients with advanced lung cancer; shares ahead 30% premarket</a></h4><ul><li>Ignyta (NASDAQ:<a href='https://seekingalpha.com/symbol/RXDX' title='Ignyta, Inc.'>RXDX</a>) is up&nbsp;<font color='green'>30%</font>&nbsp;premarket on robust volume in response its <a href=\"https://seekingalpha.com/pr/16971562-interim-analysis-ignyta-s-entrectinib-suggests-potential-best-class-profile-first-line\" target=\"_blank\">announcement </a>of updated clinical data on lung cancer candidate entrectinib. The results were presented at the 18th World Conference on Lung Cancer in Yokohama, Japan.</li><li>In non-small cell lung cancer &#40;NSCLC&#41; patients whose tumors harbor NTRK or ROS1 fusions, entrectinib demonstrated a 78% response rate as determined by the investigator and a 69% response rate confirmed independently. Median duration of response was 28.6 months and median progression-free survival was 29.6 months. 83% (n=5/6) of evaluable patients with measurable central nervous system &#40;CNS&#41; metastases at presentation responded to treatment.</li><li>CEO Jonathan Lim, M.D., says, \"Based on these data, we believe that entrectinib has the potential to be a best-in-class therapeutic option as a first-line targeted therapy for patients with ROS1-positive NSCLC. The extended duration of response and progression free survival times observed in these interim data are particularly compelling, and we believe may be driven by entrectinib&rsquo;s CNS activity. Entrectinib is designed to cross the blood-brain barrier, allowing it to both address preexisting CNS lesions and have the potential to prevent or delay the onset of metastases to the brain, a common site of progression, particularly in NSCLC.&rdquo;</li><li><a href=\"http://ignyta.com/entrectinib-trk-inhibitor/\" target=\"_blank\">Entrectinib</a>, a selective tyrosine kinase inhibitor, is being developed for the treatment of a variety of tumor types.&nbsp;<a href=\"https://en.wikipedia.org/wiki/Tyrosine_kinase\" target=\"_blank\">Tyrosine kinase</a>&nbsp;is an enzyme that serves as an \"on/off\" switch in many cellular functions. If stuck \"on\" unregulated cell growth occurs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301759\" data-linked=\"Ignyta&#39;s entrectinib shows 78% response rate in certain patients with advanced lung cancer; shares ahead 30% premarket\" data-tweet=\"$RXDX - Ignyta&#39;s entrectinib shows 78% response rate in certain patients with advanced lung cancer; shares ahead 30% premarket https://seekingalpha.com/news/3301759-ignytas-entrectinib-shows-78-response-rate-in-certain-patients-advanced-lung-cancer-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3301759-ignytas-entrectinib-shows-78-response-rate-in-certain-patients-advanced-lung-cancer-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301753\" data-ts=\"1508328596\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301753-spectrum-pharmas-poziotinib-shows-encouraging-effect-in-treatment-resistant-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma&#39;s poziotinib shows encouraging effect in treatment-resistant lung cancer patients in mid-stage study; shares ahead 28%</a></h4><ul><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) is up&nbsp;<font color='green'>28%</font>&nbsp;premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/16971561-spectrum-pharmaceuticals-highlights-poziotinib-data-non-small-cell-lung-cancer-nsclc\" target=\"_blank\">announcement </a>of positive preliminary data from a Phase 2 clinical trial assessing poziotinib in non-small cell lung cancer &#40;NSCLC&#41; patients whose tumors express exon 20 insertion mutations, a profile with a poor prognosis. The results were presented at the 18th World Conference on Lung Cancer in Yokohama, Japan.</li><li>All 11 treated patients have reached their first scan and have experienced some level of tumor shrinkage.</li><li>On the safety front, the dose of poziotinib had to be reduced in 55% (n=6) of the patients due to side effects. Adverse events included rash, diarrhea, paronychia (infection in the skin around the fingernails or toenails) and mucositis.</li><li>The company plans to meet with the FDA to discuss and clarify a regulatory pathway to approval.</li><li>Poziotinib is a pan-HER inhibitor that blocks signaling through the epidermal growth factor receptor &#40;EGFR&#41; family of tyrosine-kinase receptors, including HER receptor mutations. Its mechanism of action restricts the proliferation of tumor cells that overexpress the receptors.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301753\" data-linked=\"Spectrum Pharma&#39;s poziotinib shows encouraging effect in treatment-resistant lung cancer patients in mid-stage study; shares ahead 28%\" data-tweet=\"$SPPI - Spectrum Pharma&#39;s poziotinib shows encouraging effect in treatment-resistant lung cancer patients in mid-stage study; shares ahead 28% https://seekingalpha.com/news/3301753-spectrum-pharmas-poziotinib-shows-encouraging-effect-in-treatment-resistant-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3301753-spectrum-pharmas-poziotinib-shows-encouraging-effect-in-treatment-resistant-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301749\" data-ts=\"1508328312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301749-abbott-laboratories-q3-revenues-up-29-non-gaap-eps-up-12-updates-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abbott Laboratories Q3 revenues up 29%; non-GAAP EPS up 12%; updates guidance</a></h4><ul><li>Abbott Laboratories (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) <a href=\"https://seekingalpha.com/pr/16971818-abbott-reports-third-quarter-2017-results\" target=\"_blank\">Q3 results</a>: Revenues: $6,829M (+28.8%); Nutrition: $1,768M (+0.8%); Diagnostics: $1,279M (+5.4%); Established Pharmaceuticals: $1,171M (+15.7%); Medical Devices: $2,597M (+98.2%).</li><li>Operating Income: $810M (-9.7%); Net Income: $561M; EPS: $0.32; Non-GAAP EPS: $0.66 (+11.9%).</li><li><strong>Q4 Guidance</strong>: GAAP EPS: $0.28 - 0.30; Non-GAAP EPS: $0.72 - $0.74.</li><li><strong>2017 Guidance</strong>: GAAP EPS: $0.97 - 0.99; Non-GAAP EPS: $2.48 - $2.50.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301749\" data-linked=\"Abbott Laboratories Q3 revenues up 29%; non-GAAP EPS up 12%; updates guidance\" data-tweet=\"$ABT - Abbott Laboratories Q3 revenues up 29%; non-GAAP EPS up 12%; updates guidance https://seekingalpha.com/news/3301749-abbott-laboratories-q3-revenues-up-29-non-gaap-eps-up-12-updates-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3301749-abbott-laboratories-q3-revenues-up-29-non-gaap-eps-up-12-updates-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301741\" data-ts=\"1508327920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNBR\" target=\"_blank\">SNBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301741-select-comfort-lower-after-guidance-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Select Comfort lower after guidance disappoints</a></h4><ul> <li>Select Comfort (SCSS) falls sharply after the company narrows its FY17 EPS guidance range to $1.30 to $1.45 vs. $1.25-$1.50 prior and $1.39 consensus.</li> <li>The mattress seller also just missed estimates with its <a href=\"https://seekingalpha.com/pr/16971345-select-comfort-announces-third-quarter-2017-results\" target=\"_blank\">Q3 report</a> as operating income fell 90 bps to 9.7% of sales.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301606-select-comfort-misses-0_06-misses-revenue\" target=\"_blank\">Select Comfort misses by $0.06, misses on revenue</a> (Oct. 17)</li> <li>Shares of Select Comfort are <font color='red'>down 5.30%</font> premarket to $28.77.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301741\" data-linked=\"Select Comfort lower after guidance disappoints\" data-tweet=\"$SNBR - Select Comfort lower after guidance disappoints https://seekingalpha.com/news/3301741-select-comfort-lower-after-guidance-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3301741-select-comfort-lower-after-guidance-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301729\" data-ts=\"1508326271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301729-baml-warns-on-chipotles-labor-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML warns on Chipotle&#39;s labor costs</a></h4><ul> <li>Bank of America Merrill Lynch warns that Chipotle (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) could miss estimates due to the extra pressure of high labor costs.</li> <li>The firm thinks the restaurant operator will struggle to lower labor costs as a percentage of sales to below 27% even if it trims some hours from employee shifts.</li> <li>The BAML rating on Chipotle drops to Underperform from Neutral and the price target is slashed to $285 from $390.</li> <li>Shares of Chipotle are <font color='red'>down 2.71%</font> in premarket trading to $320.39.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3301729\" data-linked=\"BAML warns on Chipotle&#39;s labor costs\" data-tweet=\"$CMG - BAML warns on Chipotle&#39;s labor costs https://seekingalpha.com/news/3301729-baml-warns-on-chipotles-labor-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3301729-baml-warns-on-chipotles-labor-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301728\" data-ts=\"1508325983\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVS\" target=\"_blank\">CVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301728-cvs-health-inks-five-year-deal-anthem-to-support-pbm-unit-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CVS Health inks five-year deal with Anthem to support PBM unit; shares up 2% premarket</a></h4><ul><li>CVS Health (NYSE:<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume in response to its announced <a href=\"https://seekingalpha.com/pr/16971664-cvs-health-signs-five-year-agreement-anthem-inc-provide-services-support-ingeniorx\" target=\"_blank\">five-year agreement</a> with Anthem (NYSE:<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a>) to provide services to support the latter's new pharmacy benefit manager &#40;PBM&#41; IngenioRx.</li><li>CVS will be responsible for claims processing and prescription fulfillment. It will also leverage its bundled suite of assets, including CVS Pharmacy and MinuteClinic to broaden the scope of clinical services at the pharmacy counter to drive better outcomes.</li><li>The new agreement goes into effect on January 1, 2020 and runs through 2024.</li><li>CVS expects to incur implementation costs related to the transition of members but these should be immaterial to 2017 results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301728\" data-linked=\"CVS Health inks five-year deal with Anthem to support PBM unit; shares up 2% premarket\" data-tweet=\"$CVS $CVS $ANTM - CVS Health inks five-year deal with Anthem to support PBM unit; shares up 2% premarket https://seekingalpha.com/news/3301728-cvs-health-inks-five-year-deal-anthem-to-support-pbm-unit-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3301728-cvs-health-inks-five-year-deal-anthem-to-support-pbm-unit-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301726\" data-ts=\"1508325472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301726-on-supervalus-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Supervalu&#39;s Q2 results</a></h4><ul><li>Supervalu (NYSE:<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a>)&nbsp;reports Wholesale net sales rose 58% to $2.74B in <a href=\"https://seekingalpha.com/pr/16971687-supervalu-reports-second-quarter-fiscal-2018-results\" target=\"_blank\">Q2</a>, primarily due to sales from the acquired Unified Grocers business, sales to new customers and increased sales to new stores operated by existing customers.</li><li>Retail net sales squeezed 1.1% to $1.02B and identical store sales down 3.5%.</li><li>Gross margin rate fell 280 bps to 11.3% primarily due to the change in business segment mix, with Wholesale representing a larger portion of total sales and gross profit.</li><li>Adjusted SG&amp;A expense rate improved 250 bps to 9.7%.</li><li><b>FY2018 Guidance</b>: Net earnings from continuing operations: $31M to $50M; Adjusted EBITDA: $475M to $495M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3301726\" data-linked=\"More on Supervalu&#39;s Q2 results\" data-tweet=\"$SVU - More on Supervalu&#39;s Q2 results https://seekingalpha.com/news/3301726-on-supervalus-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3301726-on-supervalus-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301725\" data-ts=\"1508325437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRKR\" target=\"_blank\">PRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301725-parkervision-enters-purchase-agreement-aspire-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ParkerVision enters purchase agreement with Aspire Capital</a></h4><ul><li>        ParkerVision (<a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a>) <a href=\"https://seekingalpha.com/pr/16971766-parkervision-enters-common-stock-purchase-agreement-aspire-capital-fund\" target=\"_blank\">announces entering</a> a common stock purchase agreement with Aspire Capital.</li><li>               The agreement pertains to 312,500 shares at $1.60 per share totaling $500K.&nbsp;</li><li>               Aspire Capital also agrees to purchase up to $19.5M of additional shares.&nbsp;</li><li>                  ParkerVision shares are&nbsp;<font color='green'>up 4.73%</font>&nbsp;premarket.    &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3301725\" data-linked=\"ParkerVision enters purchase agreement with Aspire Capital\" data-tweet=\"$PRKR - ParkerVision enters purchase agreement with Aspire Capital https://seekingalpha.com/news/3301725-parkervision-enters-purchase-agreement-aspire-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3301725-parkervision-enters-purchase-agreement-aspire-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3301719\" data-ts=\"1508324691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3301719-supervalu-acquires-associated-grocers-of-florida\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supervalu acquires Associated Grocers of Florida</a></h4><ul>          <li>Supervalu&nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a>) announces that it struck an agreement to acquire Associated Grocers of Florida in a deal valued at approximately $180M.</li>     <li>The company says the transaction will help it expand its       operations into a new part of Florida as well as provides new       opportunities to bring its products and services to Associated       Grocers' diverse customer base in South Florida.</li>     <li>\"Associated Grocers represents a great opportunity for us to further       expand our wholesale business into another important region,\" says Supervalu CEO&nbsp;Mark       Gross.</li>     <li>The transaction is expected to close by the end this year.</li>     <li>SVU  <font color='green'>+3.19%</font> premarket to  $20.00.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16971693-supervalu-announces-agreement-acquire-associated-grocers-florida\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3301719\" data-linked=\"Supervalu acquires Associated Grocers of Florida\" data-tweet=\"$SVU - Supervalu acquires Associated Grocers of Florida https://seekingalpha.com/news/3301719-supervalu-acquires-associated-grocers-of-florida?source=tweet\" data-url=\"https://seekingalpha.com/news/3301719-supervalu-acquires-associated-grocers-of-florida\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}